Related Experiment Video

Updated: May 18, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Growth differentiation factor 15 in heart failure: an update

Kai C Wollert1, Tibor Kempf

  • 1Division of Molecular and Translational Cardiology, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany. wollert.kai@mh-hannover.de

Current Heart Failure Reports
|September 11, 2012
PubMed

Insights

Growth Differentiation Factor 15 (GDF-15) indicates cardiometabolic risk and heart failure (HF) risk. Elevated GDF-15 levels predict HF incidence, progression, and adverse outcomes, independent of other biomarkers.

Area of Science:

  • Cardiovascular Medicine
  • Biomarkers
  • Cytokine Signaling

Background:

  • Growth Differentiation Factor 15 (GDF-15) is a stress-responsive cytokine.
  • GDF-15 is increasingly recognized as a biomarker for cardiometabolic risk and disease burden.
  • It integrates cardiovascular and extracardiac disease pathways impacting heart failure (HF).

Purpose of the Study:

  • To review the role of GDF-15 in heart failure.
  • To highlight GDF-15 as a predictor of HF risk and prognosis.
  • To discuss the potential of GDF-15 in patient monitoring and therapeutic target discovery.

Main Methods:

  • Literature review and synthesis of existing research on GDF-15.
  • Analysis of GDF-15 levels in relation to HF incidence, progression, and outcomes.
  • Comparison of GDF-15 with established risk factors and biomarkers like BNP.

Main Results:

  • Increased circulating GDF-15 is linked to higher HF risk in healthy individuals.
  • Elevated GDF-15 post-acute coronary syndrome predicts adverse left ventricular remodeling and HF.
  • In HF patients, GDF-15 levels and their changes correlate with adverse outcomes.
  • GDF-15 provides prognostic information independent of traditional risk factors and BNP.

Conclusions:

  • GDF-15 is a significant biomarker for cardiometabolic risk and heart failure.
  • Its levels reflect disease burden and predict adverse outcomes.
  • Further research into GDF-15 pathobiology may reveal novel therapeutic targets for HF.

More Related Videos

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells09:05

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells

Published on: August 9, 2017

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...